Hypokalemia News and Research

RSS

Fenugreek seeds: A superfood for health and wellness, says new review

Research highlights the dietary significance and potential applications of fenugreek seeds, emphasizing their role in disease prevention, chronic condition management, and providing nutritional value, including their ability to reduce blood sugar and cholesterol levels.

27 Feb 2024

Novel mathematical model simulates how an average person's body regulates potassium

Having levels of potassium that are too high or too low can be fatal. A new mathematical model sheds light on the often mysterious ways the body regulates this important electrolyte.

30 Jan 2023

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

Complementary, alternative therapies for heart failure have some benefits and potential risks

There are some benefits and potentially serious risks when people with heart failure use complementary and alternative medicines (CAM), to manage symptoms, so involving the health care team is important for safety, according to a new American Heart Association scientific statement published today in the Association's flagship, peer-reviewed journal Circulation.

8 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Scientists develop nanoantidote to reduce acidosis in critically ill COVID-19 patients

A group of scientists from China has recently developed an antacid nanoantidote that can effectively ameliorate blood acidosis induced by SARS-CoV-2 infection.

11 Aug 2022

Maintaining serum potassium level may lower hazard of peritonitis in patients receiving peritoneal dialysis

This prospective, multicenter, randomized controlled trial published in the American Journal of Kidney Diseases (AJKD) demonstrated that, compared with a reactive strategy of potassium supplementation when serum potassium fell below 3.5 mEq/L, a protocol-based potassium supplementation strategy to maintain serum potassium in the target range of 4-5 mEq/L resulted in a longer time (90 days) to the first peritonitis episode, a lower hazard ratio of peritonitis, and a lesser proportion of free-peritonitis participants.

18 May 2022

Examining hypomagnesemia in critically ill patients with Acute Kidney Injury (AKI)

In this interview, News-Medical talks to Dr. Francesca Di Mario, about hypomagnesemia in critically ill patients suffering from acute kidney injuries and discusses how Nova Biomedical instruments are utilized in her work.

From Nova Biomedical 6 Apr 2022

First interchangeable biosimilar insulin product approved by FDA for treatment of diabetes

Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.

28 Jul 2021

Furin inhibition may mitigate severe COVID-19, study finds

Dr. Kara Fitzgerald, a researcher at the Institute for Functional Medicine in the United States, has explained the role of furin protease in developing severe COVID-19 illness.

20 Nov 2020

COVID-19 linked to type 1 diabetes and diabetic ketoacidosis in children

A team of researchers at Imperial College Healthcare NHS Trust and Imperial College London has found a link between COVID-19 and new-onset type 1 diabetes in children. The research is published in the journal Diabetes Care.

20 Aug 2020

Low potassium levels in COVID-19 disease

Now a new study by an Italian team of researchers published in June 2020 on the preprint server medRxiv reports that potassium levels are often low in COVID-19 disease, mostly due to the urinary loss of potassium.

17 Jun 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020

Guideline-recommended diuretic linked to more side effects than similar antihypertensive drug

Chlorthalidone, the guideline-recommended diuretic for lowering blood pressure, causes more serious side effects than hydrochlorothiazide, a similarly effective diuretic, according to a new study led by researchers at Columbia University Irving Medical Center.

17 Feb 2020

Liquorice tea linked to hypertensive emergency – a case report

An 84-year-old man was admitted with hypertensive (high blood pressure) emergency after consuming a large amount of licorice tea.

28 May 2019

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

FDA approves potassium chloride oral solution as first generic drug to receive CGT designation

The U.S. Food and Drug Administration today approved several strengths of potassium chloride oral solution as the first generic drugs to receive a Competitive Generic Therapy designation.

9 Aug 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018